

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.

Dive Brief:

- Akura Medical closed a \$53 million financing round that will be used to accelerate development of its thrombectomy technologies for blood clot removal, the company said Monday.
- The fresh funding will support the company's Katana thrombectomy system, which is intended to remove a range of clot types, and NavIQ procedural planning software.
- Qatar Investment Authority led the Series C round, in which existing investors also participated. Some of the funds will be used to set up a joint venture in Qatar.



Dive Insight:

Los Gatos, California-based Akura received an [Investigational device exemption](#) from the Food and Drug Administration in November 2024 to study the Katana system's safety and effectiveness in patients with acute pulmonary embolism. The QUADRA-PE trial [began enrolling patients](#) in February.

Pulmonary embolism is a life-threatening condition that occurs when a blood clot, typically formed in the leg, travels to the lungs, where it can block the flow of blood.



While various types of thrombectomy devices are on the market, Akura said its technologies are designed to improve procedural precision and patient outcomes.

The Katana device uses high velocity saline jets to break up clots and prevent the catheter from clogging. The platform is [designed](#) to remove both soft and hard clots. The system's sensors provide pulmonary artery pressure data during the procedure for monitoring progress.

Akura said the funding round will help it complete enrollment in the QUADRA-PE study and support its regulatory submissions. In addition, the company will continue work on its NavIQ software, which is designed to convert a CT angiogram into a 3D model of the pulmonary blood vessels.


The Series C financing follows a [\\$36 million fundraising round](#) in 2023 that was led by The Capital Partnership and Comorant Asset Management, with participation from the PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures and Shillimed angel investors.

The company [raised \\$25 million](#) in a prior financing round in 2022.

Recommended Reading

- [3 takeaways from TCT 2025](#)

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)



News | **MT**NewsWires

MannKind Seeks FDA Approval for ReadyFlow Autoinjector

MT NewsWires
December 1, 2025

In this article:

MNKD

MannKind (MNKD) said Monday the US Food and Drug

News | **MT**NewsWires

Upgrade to read this MT NewsWires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? Sign In

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

News | **MT**NewsWires

Milestone Pharmaceuticals Says US FDA Approves Cardamyst Spray for Supraventricular Tachycardia Episodes

MT NewsWires
December 16, 2025 - 1 min read

In this article:

MST

Milestone Pharmaceuticals (MST) said Friday the US Food

News | **MT**NewsWires

Upgrade to read this MT NewsWires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? Sign In

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

Recommended Stories

We're unable to load stories right now.